Clinical Trial Update: A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BMS-298585 as monotherapy in adults with Type 2 diabetes and inadequate glycemic control has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BMS-298585

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Diabetes, Type 2 | Phase 3 | Status: COMPLETED